ABSTRACT
Objective To evaluate the methods of diagnosis and treatment of thyroid disease with concomitant focal lymphocytic thyroiditis(FLT), and explore the reasons for its confused with Hashimoto′s disease(HD).Methods During the recent 25 years, 207 patients underwent surgical trearment for pathologically diagnosed HD.Among this group, 143 cases of HD with other concomitant thyroid disease were retrospectively analysed.Results Of the 143 cases, 57 cases were found to have thyroid disease with concomitant FLT, and this was 27.5%(57/207) of the total HD group, or 39.9%(57/143) of the group with thyroid disease and concomitant HD.Intraoperative pathologic section revealed that focal lymphocytic infiltration was positive in 87.7%(50/57) of cases. The postoperative hypothyroidism occurrence rate was 19.3%(11/57), of which, 7 cases(7/57, 12.3%) were subclinical hypothyroidism.Conclusions The character of pathologic changes of thyroid disease with FLT and with HD was different. Intraoperative pathologic section can be helpful in the diagnosis of this condition and can have important significance as a guide to the scope of (surgical) resection of the thyroid gland.
ABSTRACT
Objective To evaluate the relationship between the clinicopathological factors, prognosis and the expression of p16 and c erbB 2 protein in primary breast cancer. Methods The expression of p16 and c erbB 2 by immunohistochemical method was observed in 50 patients with primary breast cancer and the detection of p16 by polymerase chain reaction(PCR) and the point mutation of p16 by PCR single strand conformational polymorphism(SSCP) were detected in 20 patients with breast cancer. Results Among the cancers, positive expression of p16 protein was found in 17(34.00%) cases, c erbB 2 protein positive expression in 24(48.00%) cases. No homozygous deletion in p16 gene was found. However, exon2 point mutation of p16 gene was found in 1 of 20 breast cancer. The results showed no relationship between p16 expression and clinicopathological factor or prognosis. Positive expressions of c erbB 2 protein were often found in breast cancer with lymph node metastasis(P=0.0237) with a poor 5 year survivalrate(P=0.0169). There was no consistent relationship between the expression of p16 and c erbB 2 protein. Neither p16 nor c erbB 2 protein expression could be as an independent prognostic factor. Conclusions The patients with breast cancer of positive expression of c erbB 2 protein has a high lymph node metastasis rate and a poor survival rate. The point mutation rate of p16 gene is lower in primary breast cancer, and it can be a molecular events in advanced primary breast cancer.